# A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

> **NCT03254927** · PHASE2 · TERMINATED · sponsor: **Celldex Therapeutics** · enrollment: 30 (actual)

## Conditions studied

- Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** CDX-3379 and cetuximab

## Key facts

- **NCT ID:** NCT03254927
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-27
- **Primary completion:** 2020-09-16
- **Final completion:** 2020-12-16
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor decision based on emerging risk-benefit profile
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03254927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03254927, "A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03254927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*